Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab in MET-positive gastric cancer
NCT02137343Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 3 trial of rilotumumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Amgen. Started Jul 2014; status: terminated.
02
Drugs
rilotumumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02137343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137343.